FIELD: biotechnology.
SUBSTANCE: invention relates to the use of the anti-sclerostin antibody in the treatment of osteogenesis imperfecta (OI) in a human patient. Use involves administering to a human patient a therapeutically effective amount of a sclerostin antibody, where OI is a type I OI, a type III OI or a type IV OI, wherein the human patient has one or more mutations in the COL1A1 and/or COL1A2 genes, wherein the sclerostin antibody is administered in dose of 2–50 mg per 1 kg of the human patient’s body weight on a monthly, bi-monthly or quarterly basis.
EFFECT: invention is effective for treating osteogenesis imperfecta.
19 cl, 8 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2764981C1 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| MODIFIED IGG ANTIBODIES WHICH BIND TO A TRANSFORMING GROWTH FACTOR BETA-1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2728858C2 |
| ANTI-PRE-S1 HBV ANTIBODIES | 2016 |
|
RU2739955C2 |
| SCLEROSTIN ANTIBODY, ITS ANTIGEN-BINDING FRAGMENT AND MEDICAL APPLICATION | 2016 |
|
RU2716101C2 |
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
